Opsidio, LLC today announced the dosing of the first patient in the Phase 2a clinical trial of OpSCF, Opsidio’s pioneering monoclonal antibody against stem cell factor, in patients suffering from moderate to severe atopic dermatitis.
November 29, 2023
· 2 min read
